RU2020116307A - Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса - Google Patents

Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса Download PDF

Info

Publication number
RU2020116307A
RU2020116307A RU2020116307A RU2020116307A RU2020116307A RU 2020116307 A RU2020116307 A RU 2020116307A RU 2020116307 A RU2020116307 A RU 2020116307A RU 2020116307 A RU2020116307 A RU 2020116307A RU 2020116307 A RU2020116307 A RU 2020116307A
Authority
RU
Russia
Prior art keywords
norovirus
protein
plant
vlp
amino acid
Prior art date
Application number
RU2020116307A
Other languages
English (en)
Russian (ru)
Inventor
Пьер-Оливье Лавуа
Марк-Андре Д'АУСТ
Original Assignee
Медикаго Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медикаго Инк. filed Critical Медикаго Инк.
Publication of RU2020116307A publication Critical patent/RU2020116307A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
RU2020116307A 2017-11-30 2018-11-30 Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса RU2020116307A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593006P 2017-11-30 2017-11-30
US62/593,006 2017-11-30
US201862712744P 2018-07-31 2018-07-31
US62/712,744 2018-07-31
PCT/CA2018/051530 WO2019104439A1 (en) 2017-11-30 2018-11-30 Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins

Publications (1)

Publication Number Publication Date
RU2020116307A true RU2020116307A (ru) 2021-12-30

Family

ID=66663733

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020116307A RU2020116307A (ru) 2017-11-30 2018-11-30 Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса

Country Status (15)

Country Link
US (2) US11602558B2 (enExample)
EP (1) EP3717648A4 (enExample)
JP (2) JP7579143B2 (enExample)
KR (1) KR102878449B1 (enExample)
CN (1) CN111727255A (enExample)
AU (1) AU2018375695B2 (enExample)
BR (1) BR112020010799A2 (enExample)
CA (1) CA3083857A1 (enExample)
IL (1) IL274736A (enExample)
MX (1) MX2020005530A (enExample)
PH (1) PH12020550732A1 (enExample)
RU (1) RU2020116307A (enExample)
SG (1) SG11202004668WA (enExample)
WO (1) WO2019104439A1 (enExample)
ZA (2) ZA202003831B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2789354C1 (ru) * 2022-02-03 2023-02-01 Федеральное бюджетное учреждение науки "Нижегородский научно-исследовательский институт эпидемиологии и микробиологии им. академика И.Н. Блохиной" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения вирусоподобных частиц норовируса, содержащих белок VP1 энтеровируса Echovirus 30, in vitro

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7420339B2 (ja) * 2019-10-11 2024-01-23 学校法人北里研究所 変異ノロウイルス粒子とその生産方法
WO2022081870A1 (en) * 2020-10-14 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized norovirus virus-like particles as vaccine immunogens
CN113481328B (zh) * 2021-07-23 2023-10-27 中国科学院微生物研究所 用于检测临床样本中gi.5型诺如病毒的试剂盒及专用引物
CN118450902A (zh) * 2021-10-27 2024-08-06 宾夕法尼亚大学理事会 诺如病毒疫苗及使用方法
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用
CN118773218B (zh) * 2024-08-22 2025-09-30 中国医学科学院医学生物学研究所 一种诺如病毒gii.17型病毒样颗粒及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
DK2324113T3 (en) * 2008-08-08 2018-04-16 Takeda Vaccines Inc VIRUS-LIKE PARTICLES INCLUDING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR INCREASED CRYSTAL REACTIVITY
DK2480560T3 (en) 2009-09-22 2018-04-16 Medicago Inc PROCEDURE FOR THE PREPARATION OF PLANT DERIVATIVE PROTEINS
CN103154242B (zh) 2010-07-06 2015-09-30 诺华股份有限公司 诺如病毒衍生的免疫原性组合物和方法
EP2956169B1 (en) 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoclonal antibodies that neutralize norovirus
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US10000556B2 (en) 2013-05-09 2018-06-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use
JP5963811B2 (ja) 2014-07-18 2016-08-03 オリンパス株式会社 治療用超音波振動子
EP3037386A1 (en) 2014-12-23 2016-06-29 Casale SA A plant and a process for ammonia production with cryogenic purification, and a related method of revamping
CA2988761A1 (en) 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
EP4631970A2 (en) 2016-05-04 2025-10-15 CureVac SE Nucleic acid molecules and uses thereof
CA3056812C (en) * 2017-03-23 2022-11-29 Medicago Inc. Norovirus fusion proteins and vlps comprising norovirus fusion proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2789354C1 (ru) * 2022-02-03 2023-02-01 Федеральное бюджетное учреждение науки "Нижегородский научно-исследовательский институт эпидемиологии и микробиологии им. академика И.Н. Блохиной" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения вирусоподобных частиц норовируса, содержащих белок VP1 энтеровируса Echovirus 30, in vitro

Also Published As

Publication number Publication date
JP2024109835A (ja) 2024-08-14
PH12020550732A1 (en) 2021-04-19
KR102878449B1 (ko) 2025-10-30
SG11202004668WA (en) 2020-06-29
JP7579143B2 (ja) 2024-11-07
CN111727255A (zh) 2020-09-29
EP3717648A4 (en) 2021-12-01
MX2020005530A (es) 2021-01-15
WO2019104439A1 (en) 2019-06-06
US20230293663A1 (en) 2023-09-21
US11602558B2 (en) 2023-03-14
CA3083857A1 (en) 2019-06-06
KR20200092363A (ko) 2020-08-03
US20200330583A1 (en) 2020-10-22
ZA202003831B (en) 2023-10-25
EP3717648A1 (en) 2020-10-07
US12076388B2 (en) 2024-09-03
JP2021503962A (ja) 2021-02-15
ZA202306500B (en) 2024-10-30
IL274736A (en) 2020-07-30
AU2018375695A1 (en) 2020-06-11
AU2018375695B2 (en) 2025-01-02
BR112020010799A2 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
RU2020116307A (ru) Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса
JP2021503962A5 (enExample)
EP3319633B1 (en) Vaccine against rsv
CN1142271C (zh) 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗
HRP20231496T1 (hr) Cistein proteaza
EP3393507A1 (en) Zika virus purification
RU2007139915A (ru) Haemophilus influenzae типа в
RU2013142007A (ru) Изоляты и композиции вируса torque teno (ttv)
RU2012107993A (ru) Полипептиды porhyromonas gingivalis
JP2014519817A5 (enExample)
RU2015113826A (ru) Выделение вируса, родственного парвовирусу-2 собак, от енота
CN101879312B (zh) 广谱型流感疫苗及其制备方法
CN103540605A (zh) 重组ⅱ型猪圆环病毒的衣壳蛋白噬菌体展示颗粒及其制备方法与应用
RU2011137404A (ru) Варианты гемагглютинина и нейраминидазы гриппа
NZ712410A (en) Stabilised fmdv capsids
WO2018037246A4 (en) Immunogenic composition
RU2018112060A (ru) Слитый белок
JP2021524273A5 (enExample)
TW200716166A (en) Lawsonia intracellularis immunological proteins
RU2019113940A (ru) Мозаичные вакцины от вируса ящура серотипа а
Jia et al. Cloning, expression, purification and characterization of UL24 partial protein of duck enteritis virus
KR101933240B1 (ko) 돼지 생식기 및 호흡기 증후군 바이러스 억제용 감염 차별화 백신
JPWO2023080246A5 (enExample)
CN107365365A (zh) 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
RU2020143530A (ru) Мутанты гемагглютинина вируса гриппа